Mizuma T - Search Results

1

Kinetic impact of presystemic intestinal metabolism on drug absorption: experiment and data analysis for the prediction of in vivo absorption from in vitro data.

Mizuma T. Mizuma T. Drug Metab Pharmacokinet. 2002;17(6):496-506. doi: 10.2133/dmpk.17.496. Drug Metab Pharmacokinet. 2002. PMID: 15618704

2

Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10.

Mizuma T. Mizuma T. Int J Pharm. 2009 Aug 13;378(1-2):140-1. doi: 10.1016/j.ijpharm.2009.05.044. Epub 2009 May 30. Int J Pharm. 2009. PMID: 19486934

3

Assessment of presystemic and systemic intestinal availability of orally administered drugs using in vitro and in vivo data in humans: intestinal sulfation metabolism impacts presystemic availability much more than systemic availability of salbutamol, SULT1A3 substrate.

Mizuma T. Mizuma T. J Pharm Sci. 2008 Dec;97(12):5471-6. doi: 10.1002/jps.21363. J Pharm Sci. 2008. PMID: 18383337

4

Kinetic characterization of glycosidase activity from disaccharide conjugate to monosaccharide conjugate in Caco-2 cells.

Mizuma T, Fuseda N, Hayashi M. Mizuma T, et al. J Pharm Pharmacol. 2005 May;57(5):661-4. doi: 10.1211/0022357055948. J Pharm Pharmacol. 2005. PMID: 15901356

5

Intestinal SGLT1-mediated absorption and metabolism of benzyl beta-glucoside contained in Prunus mume: carrier-mediated transport increases intestinal availability.

Mizuma T, Nakamura M, Ina H, Miyazaki T, Hayashi M. Mizuma T, et al. Biochim Biophys Acta. 2005 Mar 11;1722(2):218-23. doi: 10.1016/j.bbagen.2004.12.011. Epub 2005 Jan 5. Biochim Biophys Acta. 2005. PMID: 15716003

6

Differentiation of organ availability by sequential and simultaneous analyses: intestinal conjugative metabolism impacts on intestinal availability in humans.

Mizuma T, Kawashima K, Sakai S, Sakaguchi S, Hayashi M. Mizuma T, et al. J Pharm Sci. 2005 Mar;94(3):571-5. doi: 10.1002/jps.20269. J Pharm Sci. 2005. PMID: 15666320

7

Does the well-stirred model assess the intestinal first-pass effect well?

Mizuma T, Tsuji A, Hayashi M. Mizuma T, et al. J Pharm Pharmacol. 2004 Dec;56(12):1597-9. doi: 10.1211/0022357044850. J Pharm Pharmacol. 2004. PMID: 15563767

8

Factors affecting glucuronidation activity in Caco-2 cells.

Mizuma T, Momota R, Haga M, Hayashi M. Mizuma T, et al. Drug Metab Pharmacokinet. 2004 Apr;19(2):130-4. doi: 10.2133/dmpk.19.130. Drug Metab Pharmacokinet. 2004. PMID: 15499179

9

Dietary polyphenols (-)-epicatechin and chrysin inhibit intestinal glucuronidation metabolism to increase drug absorption.

Mizuma T, Awazu S. Mizuma T, et al. J Pharm Sci. 2004 Sep;93(9):2407-10. doi: 10.1002/jps.20146. J Pharm Sci. 2004. PMID: 15295800

10

Concentration-dependent preferences of absorptive and excretive transport cause atypical intestinal absorption of cyclic phenylalanylserine: small intestine acts as an interface between the body and ingested compounds.

Mizuma T, Narasaka T, Hiyoshi W, Awazu S. Mizuma T, et al. Res Commun Mol Pathol Pharmacol. 2002;111(5-6):199-209. Res Commun Mol Pathol Pharmacol. 2002. PMID: 15244036

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results